TORONTO, Oct. eight, 2019 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Enterprise”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce its participation at the BMO & TMX Hemp & Health-related Cannabis Conference, taking location in in London, UK on October 16, 2019.
Alvaro Torres, Khiron CEO and director will present at the conference, and Franziska Katterbach, Khiron Chief Legal Officer (Europe) will participate in a regulatory panel. The Enterprise will also be readily available for pre-scheduled 1-on-1 meetings in the course of the conference.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis organization in Latin America. Khiron has core operations in Latin America and is totally licensed in Colombia for the cultivation, production, domestic distribution, and international export of each tetrahydrocannabinol (THC) and cannabidiol (CBD) health-related cannabis. The organization delivers very best in class regulatory compliance, has the initially authorized set of CBD cosmetic merchandise on shelf in Colombia, and is presently facilitating testing to meet and surpass all license needs for industrial cannabis derived merchandise.
With a focused regional method and patient oriented strategy, the Enterprise combines international scientific knowledge, agricultural positive aspects, branded solution market place entrance encounter and education to drive prescription and brand loyalty to address priority health-related circumstances such as chronic discomfort, epilepsy, depression and anxiousness in the Latin American market place of more than 620 million people today. The Enterprise is led by Co-founder and Chief Executive Officer, Alvaro Torres, collectively with an knowledgeable executive group, and a knowledgeable Board of Directors that consists of former President of Mexico, Vicente Fox.
This press release may well include particular “forward-hunting information and facts” and “forward-hunting statements” inside the which means of applicable securities legislation. All information and facts contained herein that is not historical in nature may well constitute forward-hunting information and facts. Khiron undertakes no obligation to comment analyses, expectations or statements created by third-parties in respect of Khiron, its securities, or monetary or operating outcomes (as applicable). Though Khiron believes that the expectations reflected in forward-hunting statements in this press release are affordable, such forward-hunting statement has been primarily based on expectations, components and assumptions regarding future events which may well prove to be inaccurate and are topic to quite a few dangers and uncertainties, particular of which are beyond Khiron’s handle, like the threat components discussed in Khiron’s Annual Data Kind which is readily available on Khiron’s SEDAR profile at www.sedar.com. The forward-hunting information and facts contained in this press release is expressly certified by this cautionary statement and are created as of the date hereof. Khiron disclaims any intention and has no obligation or duty, except as needed by law, to update or revise any forward-hunting information and facts, no matter if as a outcome of new information and facts, future events or otherwise.
United States Disclaimer
This news release does not constitute an present to sell or a solicitation of an present to invest in any of the securities in the United States. The securities have not been and will not be registered beneath the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may well not be provided or sold inside the United States or to U.S. Persons (as such term is defined in Regulation S beneath the U.S. Securities Act) unless registered beneath the U.S. Securities Act and applicable state securities laws or an exemption from such registration is readily available.
Neither the TSXV nor its Regulation Solutions Provider (as that term is defined in the policies of the TSXV) accepts duty for the adequacy or accuracy of this press release.
Additional information and facts in respect of the Enterprise can be identified at www.khiron.ca.
Supply Khiron Life Sciences Corp.